Cognition-enhancing properties of dimebon in a rat novel object recognition task are unlikely to be associated with acetylcholinesterase inhibition or N-methyl-D-aspartate receptor antagonism

Journal of Pharmacology and Experimental Therapeutics

Volumn 333, Issue 3, 2010, Pages 748-757

  Giorgetti, Marco ^a   Gibbons, Jacqueline A ^a   Bernales, Sebastián ^a,b   Alfaro, Iván E ^b   La Rochelle, Christophe Drieu ^c   Cremers, Thomas ^d   Altar, C Anthony ^e   Wronski, Robert ^f   Hutter Paier, Birgit ^f   Protter, Andrew A ^a  

^a Medivation Inc   (United States)

^b Fundacion Ciencia para la Vida   (Chile)

^c Biotrial   (France)

^d CHARLES RIVER LABORATORIES   (United States)

^e NeuroDrug Consulting   (United States)

^f JSW Life Sciences ^*  (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; CALCIUM; DIMEBON; DONEPEZIL; GALANTAMINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CALCIUM TRANSPORT; COGNITION; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG BRAIN LEVEL; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; ENZYME ANALYSIS; ENZYME INHIBITION; HIPPOCAMPUS; HYPOTHESIS; IC 50; IN VIVO STUDY; MALE; MICRODIALYSIS; NERVE CELL; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; RECOGNITION; SPRAGUE DAWLEY RAT; TASK PERFORMANCE;

ACETYLCHOLINE; ACETYLCHOLINESTERASE; ANIMALS; BEHAVIOR, ANIMAL; BRAIN CHEMISTRY; CHOLINESTERASE INHIBITORS; COGNITION; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; INDANS; INDOLES; MALE; MEMANTINE; MICRODIALYSIS; PIPERIDINES; PSYCHOMOTOR PERFORMANCE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, HISTAMINE H1; RECEPTORS, N-METHYL-D-ASPARTATE; RECOGNITION (PSYCHOLOGY);

EID: 77952387355     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.164491     Document Type: Article

References (47)

1. Arnsten AF and Cai JX (1993) Postsynaptic alpha-2 receptor stimulation improves memory in aged monkeys: indirect effects of yohimbine versus direct effects of clonidine. Neurobiol Aging 14:597-603.
2. Arnsten AF, Mathew R, Ubriani R, Taylor JR, and Li BM (1999) Alpha-1 noradrenergic receptor stimulation impairs prefrontal cortical cognitive function. Biol Psychiatry 45:26-31. (Pubitemid 29049201)
3. Bachurin S, Bukatina E, Lermontova N, Tkachenko S, Afanasiev A, Grigoriev V, Grigorieva I, Ivanov Y, Sablin S, and Zefirov N (2001) Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer. Ann N Y Acad Sci 939:425-435. (Pubitemid 32620096)
4. Bachurin SO, Shevtsova EP, Kireeva EG, Oxenkrug GF, and Sablin SO (2003) Mitochondria as a target for neurotoxins and neuroprotective agents. Ann N Y Acad Sci 993:334-344; discussion 345-349.
5. Bernales S, Alarcon R, Guerrero J, Higaki JN, and Protter AA (2009) Dimebon induces neurite outgrowth from hippocampal, spinal, and cortical neurons. Neurology 72:A385.
6. Bertaina-Anglade V, la Rochelle CD, Muñoz C, Morain P, and Bernard K (2007) Comparison of single vs. multiple administrations of the AMPA receptors modulator S 18986 in the object recognition task in rats. Fundam Clin Pharmacol 21:349-354. (Pubitemid 47084022)
7. Birks J (2006) Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev Jan 25:CD005593.
8. Brewer GJ, Torricelli JR, Evege EK, and Price PJ (1993) Optimized survival of hippocampal neurons in B27-supplemented Neurobasal, a new serum-free medium combination. J Neurosci Res 35:567-576.
9. Chaturvedi RK and Beal MF (2008) Mitochondrial approaches for neuroprotection. Ann N Y Acad Sci 1147:395-412.
10. Cremers TI, de Vries MG, Huinink KD, van Loon JP, v d Hart M, Ebert B, Westerink BH, and De Lange EC (2009) Quantitative microdialysis using modified ultraslow microdialysis: direct rapid and reliable determination of free brain concentrations with the MetaQuant technique. J Neurosci Methods 178:249-254.
11. De Backer MD, Gommeren W, Moereels H, Nobels G, Van Gompel P, Leysen JE, and Luyten WH (1993) Genomic cloning, heterologous expression and pharmacological characterization of a human histamine H1 receptor. Biochem Biophys Res Commun 197:1601-1608. (Pubitemid 24042807)
12. Dere E, Huston JP, and De Souza Silva MA (2007) The pharmacology, neuroanatomy and neurogenetics of one-trial object recognition in rodents. Neurosci Biobehav Rev 31:673-704. (Pubitemid 46670336)
13. Doody RS, Gavrilova SI, Sano M, Thomas RG, Aisen PS, Bachurin SO, Seely L, Hung D, and dimebon investigators (2008) Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet 372:207-215.
14. Ellman GL, Courtney KD, Andres V Jr, and Feather-Stone RM (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7:88-95.
15. Gjedde A (2007) Coupling of brain function to metabolism: evaluation of energy requirements, in Brain Energetics Integration of Molecular and Cellular Processes (Gibson GE and Dienel GA eds), Springer, New York.
16. Goldman ME, Jacobson AE, Rice KC, and Paul SM (1985) Differentiation of [3H]phencyclidine and (+)-[3H]SKF-10,047 binding sites in rat cerebral cortex. FEBS Lett 190:333-336. (Pubitemid 16257100)
17. Higuchi M, Yanai K, Okamura N, Meguro K, Arai H, Itoh M, Iwata R, Ido T, Watanabe T, and Sasaki H (2000) Histamine H(1) receptors in patients with Alzheimer's disease assessed by positron emission tomography. Neuroscience 99:721-729.
18. Hirst WD, Stean TO, Rogers DC, Sunter D, Pugh P, Moss SF, Bromidge SM, Riley G, Smith DR, Bartlett S, et al. (2006) SB-399885 is a potent, selective 5-HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models. Eur J Pharmacol 553:109-119. (Pubitemid 44779592)
19. Hung D (2008) Dimebon: a phase 3 investigational agent for Alzheimer's disease with a novel mitochondrial mechanism of action. Alzheimer Dementia 4:T182-T183.
20. Johnson CN, Ahmed M, and Miller ND (2008) 5-HT6 receptor antagonists: prospects for the treatment of cognitive disorders including dementia. Curr Opin Drug Discov Devel 11:642-654.
21. Kieburtz K, McDermott MP, Voss TS, Corey-Bloom J, Deuel LM, Dorsey ER, Factor S, Geschwind MD, Hodgeman K, Kayson E, et al. (2010) A randomized, placebo-controlled trial of latrepirdine in Huntington disease. Arch Neurol 67:154-160.
22. Li Z, Okamoto K, Hayashi Y, and Sheng M (2004) The importance of dendritic mitochondria in the morphogenesis and plasticity of spines and synapses. Cell 119:873-887. (Pubitemid 40017692)
23. Mattson MP, Gleichmann M, and Cheng A (2008) Mitochondria in neuroplasticity and neurological disorders. Neuron 60:748-766.
24. Mazurkiewicz-Kwilecki IM and Nsonwah S (1989) Changes in the regional brain histamine and histidine levels in postmortem brains of Alzheimer patients. Can J Physiol Pharmacol 67:75-78.
25. McShane R, Areosa Sastre A, and Minakaran N (2006) Memantine for dementia. Cochrane Database Syst Rev Apr 19:CD003154.
26. Nadarajah B (1992) The effect of pralidoxime chloride in the assay of acetylcholinesterase using 5,5′-dithio-bis(2-nitrobenzoic acid) (Ellman's reagent). J Anal Toxicol 16:192-193.
27. Nakamura S, Takemura M, Ohnishi K, Suenaga T, Nishimura M, Akiguchi I, Kimura J, and Kimura T (1993) Loss of large neurons and occurrence of neurofibrillary tangles in the tuberomammillary nucleus of patients with Alzheimer's disease. Neurosci Lett 151:196-199. (Pubitemid 23142359)
28. Oken BS, Kishiyama SS, Kaye JA, and Howieson DB (1994) Attention deficit in Alzheimer's disease is not simulated by an anticholinergic/antihistaminergic drug and is distinct from deficits in healthy aging. Neurology 44:657-662.
29. Pavlov PF, Petersen CH, Glaser E, and Ankarcrona M (2009) Mitochondrial accumulation of APP and Abeta: significance for Alzheimer disease pathogenesis. J Cell Mol Med 13:4137-4143.
30. Paxinos G and Watson C (1998) The Rat Brain in Stereotaxic Coordinates, 4th ed, Academic Press, San Diego.
31. Peskind ER, Potkin SG, Pomara N, Ott BR, Graham SM, Olin JT, and McDonald S (2006) Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry 14:704-715. (Pubitemid 44196270)
32. Pratt RD, Perdomo CA, Surick IW, and Ieni JR (2002) Donepezil: tolerability and safety in Alzheimer's disease. Int J Clin Pract 56:710-717. (Pubitemid 35414512)
33. Protter A, Vartiainen V, Yrjanheikki J, and Bernales S (2009) Neurite outgrowth and mitochondrial function in dimebon treated rat cortical cultures. Neurodegener Dis 6:A1536.
34. Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, Booker L, and Oremus M (2008) Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 148:379-397. (Pubitemid 351665469)
35. Riemer C, Borroni E, Levet-Trafit B, Martin JR, Poli S, Porter RH, and Bös M (2003) Influence of the 5-HT6 receptor on acetylcholine release in the cortex: pharmacological characterization of 4-(2-bromo-6-pyrrolidin-1- ylpyridine-4-sulfonyl)phenylamine, a potent and selective 5-HT6 receptor antagonist. J Med Chem 46:1273-1276. (Pubitemid 36428233)
36. Rösler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stähelin HB, Hartman R, and Gharabawi M (1999) Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 318:633-638. (Pubitemid 29192055)
37. Schaffhauser H, Mathiasen JR, Dicamillo A, Huffman MJ, Lu LD, McKenna BA, Qian J, and Marino MJ (2009) Dimebolin is a 5-HT6 antagonist with acute cognition enhancing activities. Biochem Pharmacol 78:1035-1042.
38. Segal M and Manor D (1992) Confocal microscopic imaging of [Ca2+]i in cultured rat hippocampal neurons following exposure to N-methyl-D-aspartate. J Physiol 448:655-676.
39. Simons FE (2004) Advances in H1-antihistamines. N Engl J Med 351:2203-2217.
40. Simons FE, Fraser TG, Reggin JD, and Simons KJ (1996) Comparison of the central nervous system effects produced by six H1-receptor antagonists. Clin Exp Allergy 26:1092-1097.
41. Sun F and Cavalli V (2009) Neuroproteomics: towards understanding neuronal regeneration and degeneration. Mol Cell Proteomics doi: 10.1074/mcp.R900003-MCP900200.
42. Swerdlow RH and Khan SM (2009) The Alzheimer's disease mitochondrial cascade hypothesis: an update. Exp Neurol 218:308-315.
43. Upton N, Chuang TT, Hunter AJ, and Virley DJ (2008) 5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer's disease. Neurotherapeutics 5:458-469. (Pubitemid 351952494)
44. van Ruitenbeek P, Vermeeren A, and Riedel W (2008) Histamine H1-receptor blockade in humans affects psychomotor performance but not memory. J Psychopharmacol 22:663-672.
45. Wilcock GK, Lilienfeld S, and Gaens E (2000) Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. BMJ 321:1445-1449.
46. Wu J, Li Q, and Bezprozvanny I (2008) Evaluation of Dimebon in cellular model of Huntington's disease. Mol Neurodegener 3:15.
47. Yanai K, Dai H, Sakurai E, and Watanabe T (2008) The roles of histamine H1 receptors on cognition. Inflamm Res 57 (Suppl 1):S39-S40.